Global Aneurysm Coiling Market Overview:
An aneurysm coil is a device inserted via a catheter to fill in a brain aneurysm a bulge in a blood vessel. Aneurysm coiling induces clotting (embolization) of the aneurysm and, in this way, prevents blood from getting into it. Aneurysm coiling prevents rupture that closes off the blood flow into the aneurysm by packing it tightly with detachable platinum coils. The factors such as Increased Prevalence of Cerebrovascular Disorders, Increased Adoption of Minimally Invasive Surgeries and Development of New Diagnostic Centres and Hospitals in Developing Countries are the key drivers for the global Aneurysm Coiling market. In addition, Rise in the Number of Surgeries Performed Worldwide also fueling the market growth. However, Complications Associated with Aneurysm Coiling may hamper the market growth.
As per latest study released by AMA Research, the Global Aneurysm Coiling market is expected to see growth rate of 10.3% and may see market size of USD2.9 Billion by 2027.
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Forecast Period | 2022-2027 |
Historical Period | 2017-2021 |
Unit | Value (USD Billion) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
Aneurysm Coiling Market Dynamics:
Attributes | Details |
---|
Growth Drivers | - Increased Prevalence of Cerebrovascular Disorders
- Increased Adoption of Minimally Invasive Surgeries
- Development of New Diagnostic Centres and Hospitals in Developing Countries
|
Restraints | - Complications Associated with Aneurysm Coiling
|
Road Blocks / Challenges | |
Gaps & Opportunities | - Increasing Number of Target Patient Population
- Growth in the Healthcare Industry Worldwide
- Increasing Incidence of Intracranial Aneurysms
|
Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Johnson and Johnson Services, Inc. (United States), MicroVention, Inc. (United States), Stryker Corporation (United States), Boston Scientific Corporation (United States), Medtronic plc (Ireland), Cardinal Health (United States), MicroPort (China), Cook Medical Incorporated (United States), B. Braun (Germany) and Integra LifeSciences (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Aneurysm Coiling market by 2027.
Latest Market Insights:
In March 2022, Johnson & Johnson today announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., and manufacturer Aspen SA Operations (Pty) Ltd, based in South Africa, to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.
In January 2021, MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB 17 System, designed with the latest microbraid technology, features a lower-profile delivery system compatible with the VIA™ 17 microcatheter and includes additional device configurations. The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intravascular flow disruptors. When placed inside the aneurysm sac, the WEB device’s proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creating a scaffold for long-lasting treatment.
In April 2019, FDA issued an order to the requester classifying the device into class II. In this final order, FDA is codifying the classification of the device by adding 21 CFR 882.5955.[1] We have named the generic type of device temporary coil embolization assist device, and it is identified as a prescription device intended for temporary use in the neurovasculature to mechanically assist in the embolization of intracranial aneurysms with embolic coils. The device is delivered into the neurovasculature with an endovascular approach. This device is not intended to be permanently implanted and is removed from the body when the procedure is completed.
What Can be Explored with the Aneurysm Coiling Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Aneurysm Coiling Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Aneurysm Coiling
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Aneurysm Coiling market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Aneurysm Coiling market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Aneurysm Coiling Devices Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.